Meeting
2022 ASCO Annual Meeting
Merkel polyoma virus specific T-cell receptor transgenic T-cell therapy in PD-1 inhibitor refractory Merkel cell carcinoma.
Authors
Joshua Veatch
Hutchinson Cancer Rsrch Ctr, Seattle, WA
Joshua Veatch , Kelly Paulson , Yuta Asano , Lauren Martin , Bo Lee , Evan Thomas Hall , Shailender Bhatia , Paul Nghiem , Aude Chapuis
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT03747484
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 9549)
DOI
10.1200/JCO.2022.40.16_suppl.9549
Abstract #
9549
Poster Bd #
142
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A phase 1 trial of umbilical cord blood–derived tumor-reactive PD-L1+ natural killer cells engineered to express soluble IL-15 (TRACK-NK) in patients with non–small-cell lung cancer (NSCLC) refractory to PD-1/PD-L1 inhibitors.
First Author: Miguel Angel Villalona-Calero
Poster
2020 ASCO Virtual Scientific Program
Phase IIa study of marrow infiltrating lymphocytes (MILs), an adoptive T cell therapy, alone or in combination with nivolumab in non-small cell lung cancer (NSCLC).
First Author: Martin Edelman
Poster
2020 ASCO Virtual Scientific Program
Open-label pilot study of genetically engineered NY-ESO-1–specific t cells (GSK3377794) alone or in combination with pembrolizumab in relapsed/refractory multiple myeloma.
First Author: Aaron Rapoport
Poster
2019 ASCO Annual Meeting
A phase I trial using CD19 CAR-T expressing PD-1/CD28 chimeric switch-receptor for refractory or relapsed B-cell lymphoma.
First Author: Hui Liu